miR-302 Attenuates Mutant Huntingtin-Induced Cytotoxicity through Restoration of Autophagy and Insulin Sensitivity.
Ching-Chi ChangSing-Hua TsouWei-Jen ChenYing-Jui HoHui-Chih HungGuang-Yaw LiuSandeep Kumar SinghHsin-Hua LiChih-Li LinPublished in: International journal of molecular sciences (2021)
Huntington's disease (HD) is an autosomal-dominant brain disorder caused by mutant huntingtin (mHtt). Although the detailed mechanisms remain unclear, the mutational expansion of polyglutamine in mHtt is proposed to induce protein aggregates and neuronal toxicity. Previous studies have shown that the decreased insulin sensitivity is closely related to mHtt-associated impairments in HD patients. However, how mHtt interferes with insulin signaling in neurons is still unknown. In the present study, we used a HD cell model to demonstrate that the miR-302 cluster, an embryonic stem cell-specific polycistronic miRNA, is significantly downregulated in mHtt-Q74-overexpressing neuronal cells. On the contrary, restoration of miR-302 cluster was shown to attenuate mHtt-induced cytotoxicity by improving insulin sensitivity, leading to a reduction of mHtt aggregates through the enhancement of autophagy. In addition, miR-302 also promoted mitophagy and stimulated Sirt1/AMPK-PGC1α pathway thereby preserving mitochondrial function. Taken together, these results highlight the potential role of miR-302 cluster in neuronal cells, and provide a novel mechanism for mHtt-impaired insulin signaling in the pathogenesis of HD.
Keyphrases
- cell proliferation
- long non coding rna
- long noncoding rna
- induced apoptosis
- oxidative stress
- stem cells
- type diabetes
- endoplasmic reticulum stress
- cell death
- cell cycle arrest
- signaling pathway
- diabetic rats
- skeletal muscle
- high glucose
- cerebral ischemia
- spinal cord
- endothelial cells
- drug induced
- glycemic control
- small molecule
- multiple sclerosis
- climate change
- amino acid
- nlrp inflammasome
- brain injury
- human health
- patient reported
- insulin resistance
- protein kinase
- oxide nanoparticles
- case control